Overview

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV treatment study.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Anti-Retroviral Agents
Elvitegravir
Ritonavir